Related Experiment Video

Updated: Jul 5, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Role of functional polymorphisms of NRAMP1 gene for the development of Crohn's disease

Maria Gazouli1, Vassilios Atsaves, Gerassimos Mantzaris

  • 1Department of Biology, School of Medicine, University of Athens, Greece. mgazouli@med.uoa.gr

Inflammatory Bowel Diseases
|May 6, 2008
PubMed
Abstract

Insights

Genetic variations in the Natural Resistance-Associated Macrophage Protein 1 (NRAMP1) gene are linked to Crohn's disease (CD) susceptibility. Specific NRAMP1 polymorphisms correlate with increased NRAMP1 expression, potentially driving CD pathogenesis.

Area of Science:

  • Genetics
  • Immunology
  • Gastroenterology

Background:

  • Crohn's disease (CD) involves chronic macrophage activation.
  • The NRAMP1 gene influences macrophage function and innate immunity.
  • NRAMP1 polymorphisms have been linked to autoimmune disorders.

Purpose of the Study:

  • To investigate NRAMP1 as a genetic determinant for CD in a Greek population.
  • To compare NRAMP1 allele frequencies in CD patients versus healthy controls.

Main Methods:

  • Genotyping of NRAMP1 polymorphisms, including 5'(GT)n and others.
  • Analysis of NRAMP1 mRNA levels via RT-PCR.
  • Assessment of NRAMP1 protein expression using immunohistochemistry.

Main Results:

  • Three NRAMP1 polymorphisms (5'(GT)n, D543N, INT4G/C) showed significant association with CD.
  • Allele 3 of the 5'(GT)n promoter polymorphism was linked to increased CD risk (OR 1.50, P=0.002).
  • CD patients with allele 3 exhibited higher NRAMP1 mRNA and protein levels.

Conclusions:

  • Genetic polymorphisms in NRAMP1 are associated with susceptibility to Crohn's disease.
  • Elevated NRAMP1 expression due to specific alleles may contribute to CD pathogenesis.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...